Lutris Pharma
PrivateLast Round
VC Round
Jan 28, 2025
Total Funding Raised
$5M
Company Overview
Lutris Pharma is a clinical-stage biopharmaceutical company that develops novel topical therapies to mitigate the side effects of anti-cancer treatments such as EGFR inhibitors and radiation.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Lutris Pharma Comparables
Compare Lutris Pharma with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Hoth Therapeutics Inc | 84% | |
| VasoDynamics Ltd | 81% | |
| Alys Pharmaceuticals | 81% |
Lutris Pharma Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| VC Round | Jan 28, 2025 | ||||
| Grant | Oct 24, 2022 | ||||
| VC Round | Jan 1, 2020 | ||||
| Seed | May 1, 2016 |
Lutris Pharma Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Pontifax Venture Capital | VC Round, Seed |
| aMoon | VC Round |
| California Institute for Regenerative Medicine | Grant |
| Peregrine Ventures | VC Round |
| Columbus Venture Partners | VC Round |
| Arkin Capital | VC Round, Seed |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 12, 2026
Monthly visitors increased 118% MoM.
- Jul 7, 2025
Presented data at the ESMO Gastrointestinal Cancers Congress 2025.
Recent news
Latest coverage and updates
- attends_eventOct 1, 2026
Lutris Pharma will present updated Phase 2 data on LUT014 gel for EGFRI-induced acneiform rash at the EADV Congress in Austria, held Sep 30th-Oct 3rd '26.
Lutris Pharma Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Lutris Pharma's valuation, stock price, and market status.
Is Lutris Pharma a public or private company?
Lutris Pharma is a private company.
What is the current stock price of Lutris Pharma?
Lutris Pharma is a private company, so its shares have no public market price. Caplight tracks Lutris Pharma's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Lutris Pharma worth (valuation)?
Valuation information for Lutris Pharma is not publicly available.
Can I buy Lutris Pharma stock?
Lutris Pharma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Lutris Pharma's last funding round?
Lutris Pharma's most recent funding round was VC Round on January 28, 2025.
Who are the main investors in Lutris Pharma?
Key investors in Lutris Pharma include Pontifax Venture Capital, Columbus Venture Partners.
Will Lutris Pharma IPO soon?
No public IPO plans have been announced for Lutris Pharma.
How can I track Lutris Pharma secondary market activity?
Caplight tracks bids, offers, and trades in Lutris Pharma's shares on secondary markets.